×
S&P 500   3,895.46 (-0.12%)
DOW   31,495.56 (+0.18%)
QQQ   290.76 (-0.58%)
AAPL   140.87 (-0.56%)
MSFT   262.20 (-1.02%)
META   168.97 (-0.31%)
GOOGL   2,286.07 (-1.32%)
AMZN   111.09 (-1.88%)
TSLA   729.95 (-0.65%)
NVDA   164.95 (-2.22%)
NIO   22.38 (-2.48%)
BABA   119.60 (+0.73%)
AMD   82.87 (-3.82%)
MU   59.45 (+1.14%)
CGC   3.74 (-1.32%)
T   20.94 (+0.77%)
GE   67.26 (+0.82%)
F   12.22 (+1.50%)
DIS   100.10 (+3.61%)
AMC   13.67 (-3.26%)
PFE   51.39 (-0.94%)
PYPL   74.98 (-1.26%)
NFLX   186.29 (-1.51%)
S&P 500   3,895.46 (-0.12%)
DOW   31,495.56 (+0.18%)
QQQ   290.76 (-0.58%)
AAPL   140.87 (-0.56%)
MSFT   262.20 (-1.02%)
META   168.97 (-0.31%)
GOOGL   2,286.07 (-1.32%)
AMZN   111.09 (-1.88%)
TSLA   729.95 (-0.65%)
NVDA   164.95 (-2.22%)
NIO   22.38 (-2.48%)
BABA   119.60 (+0.73%)
AMD   82.87 (-3.82%)
MU   59.45 (+1.14%)
CGC   3.74 (-1.32%)
T   20.94 (+0.77%)
GE   67.26 (+0.82%)
F   12.22 (+1.50%)
DIS   100.10 (+3.61%)
AMC   13.67 (-3.26%)
PFE   51.39 (-0.94%)
PYPL   74.98 (-1.26%)
NFLX   186.29 (-1.51%)
S&P 500   3,895.46 (-0.12%)
DOW   31,495.56 (+0.18%)
QQQ   290.76 (-0.58%)
AAPL   140.87 (-0.56%)
MSFT   262.20 (-1.02%)
META   168.97 (-0.31%)
GOOGL   2,286.07 (-1.32%)
AMZN   111.09 (-1.88%)
TSLA   729.95 (-0.65%)
NVDA   164.95 (-2.22%)
NIO   22.38 (-2.48%)
BABA   119.60 (+0.73%)
AMD   82.87 (-3.82%)
MU   59.45 (+1.14%)
CGC   3.74 (-1.32%)
T   20.94 (+0.77%)
GE   67.26 (+0.82%)
F   12.22 (+1.50%)
DIS   100.10 (+3.61%)
AMC   13.67 (-3.26%)
PFE   51.39 (-0.94%)
PYPL   74.98 (-1.26%)
NFLX   186.29 (-1.51%)
S&P 500   3,895.46 (-0.12%)
DOW   31,495.56 (+0.18%)
QQQ   290.76 (-0.58%)
AAPL   140.87 (-0.56%)
MSFT   262.20 (-1.02%)
META   168.97 (-0.31%)
GOOGL   2,286.07 (-1.32%)
AMZN   111.09 (-1.88%)
TSLA   729.95 (-0.65%)
NVDA   164.95 (-2.22%)
NIO   22.38 (-2.48%)
BABA   119.60 (+0.73%)
AMD   82.87 (-3.82%)
MU   59.45 (+1.14%)
CGC   3.74 (-1.32%)
T   20.94 (+0.77%)
GE   67.26 (+0.82%)
F   12.22 (+1.50%)
DIS   100.10 (+3.61%)
AMC   13.67 (-3.26%)
PFE   51.39 (-0.94%)
PYPL   74.98 (-1.26%)
NFLX   186.29 (-1.51%)
NASDAQ:PHIO

Phio Pharmaceuticals Stock Forecast, Price & News

$0.74
+0.02 (+2.78%)
(As of 06/28/2022 11:04 AM ET)
Add
Compare
Today's Range
$0.73
$0.80
50-Day Range
$0.65
$1.32
52-Week Range
$0.62
$2.47
Volume
900 shs
Average Volume
173,907 shs
Market Capitalization
$10.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
30 days | 90 days | 365 days | Advanced Chart

Receive PHIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Phio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHIO Stock Forecast (MarketRank)

Overall MarketRank

2.03 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 2.5 5 -4 -3 -2 -1 -
Phio Pharmaceuticals logo

About Phio Pharmaceuticals (NASDAQ:PHIO)

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

PHIO Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PHIO
Employees
12
Year Founded
N/A

Company Calendar

Last Earnings
5/13/2022
Today
6/28/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+710.8%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-13.29 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$20 thousand
Book Value
$1.62 per share

Miscellaneous

Free Float
13,618,000
Market Cap
$10.11 million
Optionable
Not Optionable
Beta
1.69














Phio Pharmaceuticals Frequently Asked Questions

Should I buy or sell Phio Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Phio Pharmaceuticals stock.
View analyst ratings for Phio Pharmaceuticals
or view top-rated stocks.

What is Phio Pharmaceuticals' stock price forecast for 2022?

1 brokers have issued 1-year price objectives for Phio Pharmaceuticals' stock. Their PHIO stock forecasts range from $6.00 to $6.00. On average, they predict Phio Pharmaceuticals' stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 710.8% from the stock's current price.
View analysts' price targets for Phio Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Phio Pharmaceuticals' stock performed in 2022?

Phio Pharmaceuticals' stock was trading at $1.00 at the beginning of 2022. Since then, PHIO stock has decreased by 26.0% and is now trading at $0.74.
View the best growth stocks for 2022 here
.

Are investors shorting Phio Pharmaceuticals?

Phio Pharmaceuticals saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 246,400 shares, a decline of 33.2% from the May 31st total of 368,700 shares. Based on an average daily trading volume, of 3,440,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 1.9% of the company's shares are short sold.
View Phio Pharmaceuticals' Short Interest
.

When is Phio Pharmaceuticals' next earnings date?

Phio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Phio Pharmaceuticals
.

How were Phio Pharmaceuticals' earnings last quarter?

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) posted its quarterly earnings data on Friday, May, 13th. The company reported ($0.19) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.11.
View Phio Pharmaceuticals' earnings history
.

Who are Phio Pharmaceuticals' key executives?

Phio Pharmaceuticals' management team includes the following people:
  • Ms. Caitlin Kontulis, VP of Fin. & Admin. and Sec. (Age 36)

What other stocks do shareholders of Phio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Ocugen (OCGN), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Boxlight (BOXL), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC), Jaguar Health (JAGX) and Milestone Pharmaceuticals (MIST).

What is Phio Pharmaceuticals' stock symbol?

Phio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHIO."

Who are Phio Pharmaceuticals' major shareholders?

Phio Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.23%), Cetera Investment Advisers (0.66%), Renaissance Technologies LLC (0.30%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Phio Pharmaceuticals stock include Gerrit Dispersyn and Robert L Ferrara.
View institutional ownership trends for Phio Pharmaceuticals
.

Which major investors are buying Phio Pharmaceuticals stock?

PHIO stock was acquired by a variety of institutional investors in the last quarter, including Cetera Investment Advisers, Renaissance Technologies LLC, and Vanguard Group Inc.. Company insiders that have bought Phio Pharmaceuticals stock in the last two years include Gerrit Dispersyn, and Robert L Ferrara.
View insider buying and selling activity for Phio Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Phio Pharmaceuticals?

Shares of PHIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Phio Pharmaceuticals' stock price today?

One share of PHIO stock can currently be purchased for approximately $0.74.

How much money does Phio Pharmaceuticals make?

Phio Pharmaceuticals (NASDAQ:PHIO) has a market capitalization of $10.11 million and generates $20 thousand in revenue each year. The company earns $-13.29 million in net income (profit) each year or ($0.920010) on an earnings per share basis.

How many employees does Phio Pharmaceuticals have?

Phio Pharmaceuticals employs 12 workers across the globe.

How can I contact Phio Pharmaceuticals?

Phio Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The official website for Phio Pharmaceuticals is phiopharma.com. The company can be reached via phone at (508) 767-3861, via email at [email protected], or via fax at 508-767-3862.

This page (NASDAQ:PHIO) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.